NuView Radiopharmaceuticals

NuView Radiopharmaceuticals is a clinical-stage biotechnology company dedicated to the development of precision oncology diagnostics and therapeutics. The company's core technology is centered on the NV-VPAC1 platform, which utilizes a small peptide analogue to target the Vasoactive Intestinal Peptide Receptor 1 (VPAC1) that is overexpressed on the surface of many types of cancer cells. NuView is advancing a dual-track approach that includes in vitro diagnostics, such as a non-invasive liquid biopsy for bladder cancer, and in vivo applications for molecular imaging and targeted radiopharmaceutical therapy. By leveraging the specific expression of VPAC1, the company aims to provide more accurate cancer detection and highly localized treatment options for patients with solid tumors.